Targeting of C-ROS-1 Activity Using a Controlled Release Carrier to Treat Craniosynostosis in a Preclinical Model of Saethre-Chotzen Syndrome

Figure 5

No significant adverse effects following CMC + crizotinib treatment. Measurement of blood parameters: (a) white blood cells (WBCs), (b) red blood cells (RBCs), (c) haemaglobin (HB), and (d) platelets were assessed for whole blood taken from 25-day-old mice following local implantation of CMC microdisks containing either 0.1% DMSO or 1–4 μM crizotinib at P8. Values are the mean ± SEM, one-way ANOVA with Tukey’s multiple comparisons, DF = 3, (a) F = 3.812 (1 μM Crizo, ; 2 μM Crizo, ; 4 μM Crizo, p = 0.576), (b) F = 0.791 (1 μM Crizo, ; 2 μM Crizo, ; 4 μM Crizo, ), (c) F = 0.557 (1 μM Crizo, p = 0.932; 2 μM Crizo, p = 0.855; 4 μM Crizo, p = 0.894), (d) F = 1.652 (1 μM Crizo, ; 2 μM Crizo, ; 4 μM Crizo, ), n = 7–8 mice/treatment group. Representative histological sections of H&E stained (e) brain tissue, (f) liver tissue, (g) kidney tissue, and (h) spleen tissue harvested from 25-day-old mice following local implantation of CMC microdisks containing either 0.1% DMSO or 1-4 μM crizotinib at P8, scale bar = 50 μm (100×).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)